SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stephen P.H. Alexander, The Endocannabinoidome, 2015,

    CrossRef

  2. 2
    C. D’Addario, M.V. Micioni Di Bonaventura, M. Pucci, A. Romano, S. Gaetani, R. Ciccocioppo, C. Cifani, M. Maccarrone, Endocannabinoid signaling and food addiction, Neuroscience & Biobehavioral Reviews, 2014, 47, 203

    CrossRef

  3. 3
    Zhongyi Chen, Lilu Guo, Yongqin Zhang, Rosemary L. Walzem, Julie S. Pendergast, Richard L. Printz, Lindsey C. Morris, Elena Matafonova, Xavier Stien, Li Kang, Denis Coulon, Owen P. McGuinness, Kevin D. Niswender, Sean S. Davies, Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity, Journal of Clinical Investigation, 2014, 124, 8, 3391

    CrossRef

  4. 4
    Raffaele Capasso, Pierangelo Orlando, Ester Pagano, Teresa Aveta, Lorena Buono, Francesca Borrelli, Vincenzo Di Marzo, Angelo A Izzo, Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels, British Journal of Pharmacology, 2014, 171, 17
  5. 5
    Harald S. Hansen, Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat, Pharmacological Research, 2014, 86, 18

    CrossRef

  6. 6
    Daniele Piomelli, A fatty gut feeling, Trends in Endocrinology & Metabolism, 2013, 24, 7, 332

    CrossRef

  7. You have free access to this content7
    Saoirse Elizabeth O'Sullivan, Cannabinoid activation of peroxisome proliferator-activated receptors: an update and review of the physiological relevance, Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, 2013, 2, 1
  8. 8
    B.M. Fonseca, M.A. Costa, M. Almada, G. Correia-da-Silva, N.A. Teixeira, Endogenous cannabinoids revisited: A biochemistry perspective, Prostaglandins & Other Lipid Mediators, 2013, 102-103, 13

    CrossRef

  9. 9
    Shaan S. Naughton, Michael L. Mathai, Deanne H. Hryciw, Andrew J. McAinch, Fatty Acid Modulation of the Endocannabinoid System and the Effect on Food Intake and Metabolism, International Journal of Endocrinology, 2013, 2013, 1

    CrossRef

  10. 10
    Ainhoa Bilbao, Eduardo Blanco, María Jesús Luque-Rojas, Juan Suárez, Ana Palomino, Margarita Vida, Pedro Araos, Francisco J. Bermúdez-Silva, Emilio Fernández-Espejo, Rainer Spanagel, Fernando Rodríguez de Fonseca, Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism, Addiction Biology, 2013, 18, 1
  11. 11
    Jessica Ruiz-Medina, Juan A. Flores, Inmaculada Tasset, Isaac Tunez, Olga Valverde, Emilio Fernandez-Espejo, Alteration of neuropathic and visceral pain in female C57BL/6J mice lacking the PPAR-α gene, Psychopharmacology, 2012, 222, 3, 477

    CrossRef

  12. 12
    M Bashashati, MA Storr, SP Nikas, JT Wood, G Godlewski, J Liu, W Ho, CM Keenan, H Zhang, SO Alapafuja, BF Cravatt, B Lutz, K Mackie, G Kunos, KD Patel, A Makriyannis, JS Davison, KA Sharkey, Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice, British Journal of Pharmacology, 2012, 165, 5
  13. 13
    Angelo A Izzo, Raffaele Capasso, Gabriella Aviello, Francesca Borrelli, Barbara Romano, Fabiana Piscitelli, Laura Gallo, Francesco Capasso, Pierangelo Orlando, Vincenzo Di Marzo, Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice, British Journal of Pharmacology, 2012, 166, 4
  14. You have free access to this content14
    Virginia M Stone, Shalinee Dhayal, David M Smith, Carol Lenaghan, Katy J Brocklehurst, Noel G Morgan, The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119, British Journal of Pharmacology, 2012, 165, 8
  15. 15
    David R Janero, Loren Lindsley, Venkata Kiran Vemuri, Alexandros Makriyannis, Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk, Expert Opinion on Drug Discovery, 2011, 6, 10, 995

    CrossRef

  16. You have free access to this content16
    V. Di Marzo, F. Piscitelli, Gut feelings about the endocannabinoid system, Neurogastroenterology & Motility, 2011, 23, 5
  17. 17
    Angelo A. Izzo, Keith A. Sharkey, Cannabinoids and the gut: New developments and emerging concepts, Pharmacology & Therapeutics, 2010, 126, 1, 21

    CrossRef

  18. 18
    Pasqua Dipasquale, Adele Romano, Silvia Cianci, Laura Righetti, Silvana Gaetani, Oleoylethanolamide: a new player in energy metabolism control. Role in food intake, Drug Discovery Today: Disease Mechanisms, 2010, 7, 3-4, e169

    CrossRef

  19. 19
    Francisco Javier Pavón, Antonia Serrano, Miguel Romero-Cuevas, Mónica Alonso, Fernando Rodríguez de Fonseca, Oleoylethanolamide: a new player in peripheral control of energy metabolism. Therapeutic implications, Drug Discovery Today: Disease Mechanisms, 2010, 7, 3-4, e175

    CrossRef

  20. 20
    N. Marsollier, Des phospholipides entérocytaires en tant que nouvelles molécules régulant l’homéostasie énergétique, Obésité, 2009, 4, 2, 142

    CrossRef